US biotech giant Amgen and Germany’s Immatics Biotechnologies GmbH have announced a deal potentially worth more than $1.3 billion to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.
Read More
UK biopharma Kymab has signed a cross-licensing and development deal with Shanghai-based EpimAb Biotherapeutics to develop bispecific therapeutic antibodies against multiple targets.
Read More
Novartis has signed a collaboration and licensing deal with California biotech Xencor for access to its bispecific antibody technology and rights to develop and commercialise two of the latter’s flagship experimental therapeutics.
Read More
